Mesoblast Financial Results Webcast for Period Ended March 31, 2019
May 30 2019 - 6:00AM
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial
results for the period ended March 31, 2019 in a webcast beginning
at 6:30pm on Thursday, May 30, 2019 EDT; 8:30am Friday, May 31,
2019 AEST.
The live webcast can be accessed via
https://webcasting.boardroom.media/broadcast/5ce635514b5ab5633996c030
To access the call only, dial 1 855 881 1339 (U.S.), 1 800 558
698 (toll-free Australia) or +61 2 9007 3187 (outside of the U.S.
and Australia). The conference identification code is 10000574.
The archived webcast will be available on the Investor page of
the Company’s website – www.mesoblast.com
About Mesoblast Mesoblast
Limited (Nasdaq: MESO; ASX: MSB) is a world leader in developing
allogeneic (off-the-shelf) cellular medicines. The Company has
leveraged its proprietary technology platform to establish a broad
portfolio of late-stage product candidates with three product
candidates in Phase 3 trials – acute graft versus host disease,
chronic heart failure and chronic low back pain due to degenerative
disc disease. Through a proprietary process, Mesoblast selects rare
mesenchymal lineage precursor and stem cells from the bone marrow
of healthy adults and creates master cell banks, which can be
industrially expanded to produce thousands of doses from each donor
that meet stringent release criteria, have lot to lot consistency,
and can be used off-the-shelf without the need for tissue matching.
Mesoblast has facilities in Melbourne, New York, Singapore and
Texas and is listed on the Australian Securities Exchange (MSB) and
on the Nasdaq (MESO). www.mesoblast.com
For further information, please contact:
Julie Meldrum |
Schond Greenway |
Corporate Communications |
Investor Relations |
Mesoblast |
Mesoblast |
T: +61 3 9639 6036 |
T: +1 212 880 2060 |
E:
julie.meldrum@mesoblast.com |
E:
schond.greenway@mesoblast.com |
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Jul 2023 to Jul 2024